^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Lung Adenocarcinoma
    Drug Class:FASN inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Lung Cancer
    Title:

    Loss of wild type KRAS in KRAS MUT lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors

    Published date:
    01/02/2021
    Excerpt:
    ...we termed loss of heterozygosity (LOH) for any RAS (LAR) or LAKR in the context of KRAS (LOH at KRAS), is found in patients with RASMUT cancers….KRAS MUT LUAD cells with LAKR showed higher sensitivity to treatment with FASN inhibitors than those without.
    DOI:
    10.1016/j.lungcan.2020.12.032